Find a Clinical Trial

Showing 111 - 120 of 234 Trials

Randomized Phase 2 trial of Isatuximab during Autologous Stem Cell Collection and Transplantation Period in patients with Multiple Myeloma and Lymphoma

Principal Investigator:

Divaya Bhutani, MD

Contact Number:

212-342-5162

NCT Number:

NCT05346809

Population:

Adult

Phase:

II

The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm), Participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each Participant will have about 66% chance of getting...
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT05890352

Population:

Adult

Phase:

II

The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large b-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of tazemetostat or zanubrutinib to the usual treatment could shrink the cancer or extend your time without cancer symptoms coming back. But it may also cause side effects, which the doctors will monitor. This study will help the study doctors find out...
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT05682443

Population:

Adult

Phase:

II

The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO® (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO® alone. ONC-392 has not yet been approved by the Food and Drug Administration (FDA). PLUVICTO® is FDA approved but is not approved to be combined with ONC-392. Are you Eligible? (Inclusion Criteria) Male 18 years or older -Confirmed prostate adenocarcinoma -Have had previous...
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Principal Investigator:

Eileen Patricia Connolly, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT03598257

Population:

Adult

Phase:

II

This study is being done to answer the following question: Can we lower the chance of your cancer returning by adding the drug Olaparib to the usual radiation therapy for your cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your inflammatory breast cancer. The usual approach is defined as care most people get for inflammatory breast cancer when they have already received chemotherapy and had surgery to remove the cancer. Are you Eligible? (Inclusion Criteria) To be considered for this trial, subjects must have:...
Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients

Principal Investigator:

Nicole Lamanna, MD

Contact Number:

212-342-5162

NCT Number:

NCT04419519

Population:

Adult

Phase:

II

The purpose of this study is to find out whether people who are currently receiving treatment with venetoclax can stop treatment and remain off-treatment for at least 12 months, if they are free of residual disease (MRD- negative) when they stop treatment. Are you Eligible? (Inclusion Criteria) > 18-years-old Diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma confirmed by the enrolling institution Receiving treatment with a venetoclax-based regimen as defined below: - Venetoclax monotherapy (therapy that uses one type of treatment) Venetoclax in combination with anti...
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT02693535

Population:

Adult

Phase:

II

Many research studies are done to try to find the best way to treat patients with cancer. Researchers are working on new anticancer agents that are targeted to the genes in a person’s tumor. Genes are the basic “instruction book” for the cells that make up our bodies and are made out of DNA. DNA contains information that determines things such as eye and hair color. DNA is made up of long strands of repeating letters that form a code. The order of these letters in DNA is important. In the same way that a spelling mistake in a word could change its meaning (for example, mean...
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

Principal Investigator:

Yoanna S Pumpalova, MD

Contact Number:

212-342-5162

NCT Number:

NCT05610163

Population:

Adult

Phase:

II

This study is being done to answer the following question: Can we increase the clinical complete response rate (tumor disappears by exam, endoscopy, and imaging) by adding a 3rd drug (irinotecan) to the standard chemotherapy regimens known as FOLFOX or CAPOX, given following long-course chemoradiation for patients with locally advanced rectal cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your rectal cancer. The usual approach is defined as care most people get for locally advanced rectal cancer. Are you Eligible? (...
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis System as an interventional therapy for the treatment of CTCL (Mycosis Fungoides) in patients with TMN classification stage IA, IB or IIA, an open-label,

Principal Investigator:

Larisa J. Geskin, MD

Contact Number:

212-342-5162

NCT Number:

NCT05680558

Population:

Adult

Phase:

II

To assess the efficacy of the UVAR® THERAKOS® CELLEX Photopheresis System to treat early stage (IA, IB or IIA) cutaneous T-cell lymphoma (CTCL) using the modified skin-weighted assessment tool (mSWAT) to determine overall response. Are you Eligible? (Inclusion Criteria) This study will include patients who have the diagnosis of Mycosis Fungoides (including confirmatory biopsy) and are over the age of 18. Patients must have the appropriate staging (IA, IB or IIA) and be refractory to at least one of the standard therapies used to treat Mycosis Fungoides. Patients must not be on any...
ZN-c3-005_GOG 3066-DENALI: A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN‑c3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05128825

Population:

Adult

Phase:

II

Participants are being invited to take part in a clinical research study because they have been diagnosed with locally advanced or metastatic solid tumors with mutations in the following genes: MRE11, RAD50, NBN or CCNE1 amplification. If the participant takes part in the study, they will take an investigational drug referred to as ZN-c3 (“Study Drug”). ‘Investigational’ means that the Study Drug is currently being tested and has not been approved by the U.S. Food and Drug Administration (FDA) or any other health or regulatory authority in other countries. The purpose...
A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKERADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITHLENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORYFOLLICULAR LYMPHOMA

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT04224493

Population:

Adult

Phase:

I/III

The purpose of the study is to evaluate the safety and tolerability of tazemetostat in combination with lenalidomide + rituximab in patients with follicular lymphoma that has returned or has not responded to treatment (relapsed/refractory). The study will also try to select a recommended phase 3 dose of tazemetostat for further evaluation. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have follicular lymphoma? Has your disease relapsed or progressed during/after treatment? Are you able to take oral medication?

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages